Breaking News: CMPS latest news.

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Compass Pathways appoints Wayne Riley to board of directors » 07:11 04/01/21 04/01 07:11 04/01/21 07:11 CMPS Compass Pathways $36.93 / +1.54 (+4.35%) Compass Pathways… Compass Pathways announced that it has appointed Wayne Riley MD to its board of directors. Riley is President of the State University of New York Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. In addition, Riley is also chairman of the board of the New York Academy of Medicine, an elected member of the US National Academy of Medicine, a Commissioner of the US Medicare Payment Advisory Commission, and President of the Society of Medical Administrators. He is a President Emeritus of the American College of Physicians. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Options CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 03/23/21 Compass announces USPTO grants patents for psilocybin in depression treatment 02/09/21 Compass Pathways expands Discovery Center through lab collaborations 02/03/21 Compass announces publication on therapist training program for psilocybin 01/08/21 Compass Pathways establishes Center of Excellence with Sheppard Pratt CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 04/01/21 Roth Capital Compass Pathways initiated with a Buy at Roth Capital 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 03/09/21 Compass Pathways reports Q4 EPS (52c), consensus ($1.05) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 10/21/20 Eleven new option listings and one option delisting on October 21st
Initiation	Compass Pathways initiated with a Buy at Roth Capital » 06:58 04/01/21 04/01 06:58 04/01/21 06:58 CMPS Compass Pathways $36.93 / +1.54 (+4.35%) Roth Capital analyst… Roth Capital analyst Elemer Piros initiated coverage of Compass Pathways with a Buy rating and $88 price target. Compass is at the "forefront" of bringing the first psychedelic drug to market for treatment-resistant depression, Piros tells investors in a research note. He believes the company is "leading the way" to properly evaluate gaining eventual approval of psychedelic drugs for mental illness. Compass has obtained Breakthrough Therapy designation for psilocybin in treatment-resistant depression and plans to complete a 216-patient Phase 2b trial by the end of 2021, Piros notes. With a "relatively small," 5% penetration, the company could achieve $8B in sales in the U.S. and Europe combined, says the analyst. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Options CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 03/23/21 Compass announces USPTO grants patents for psilocybin in depression treatment 02/09/21 Compass Pathways expands Discovery Center through lab collaborations 02/03/21 Compass announces publication on therapist training program for psilocybin 01/08/21 Compass Pathways establishes Center of Excellence with Sheppard Pratt CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 03/09/21 Compass Pathways reports Q4 EPS (52c), consensus ($1.05) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research CMPS Compass Pathways $36.93 / +1.54 (+4.35%) 10/21/20 Eleven new option listings and one option delisting on October 21st
Hot Stocks	Compass announces USPTO grants patents for psilocybin in depression treatment » 08:17 03/23/21 03/23 08:17 03/23/21 08:17 CMPS Compass Pathways $38.27 / -1.24 (-3.14%) Compass Pathways… Compass Pathways announced that it has been granted two new patents by the US Patent and Trademark Office . These patents cover oral formulations of COMPASS's synthetic psilocybin in the treatment of major depressive disorder, which includes treatment-resistant depression. US Patent No 10,954,259 was granted on 23 March 2021, with claims to COMPASS's high-purity crystalline psilocybin, pharmaceutical formulations containing crystalline psilocybin and methods of treating MDD with the crystalline psilocybin. US Patent No 10,947,257 was granted on 16 March 2021, with claims to oral dosage forms of crystalline psilocybin and methods of treating MDD with the oral dosage forms. "These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US," said George Goldsmith, CEO and Co-founder of COMPASS Pathways. "Through these grants, the USPTO has recognised our innovations. These decisions enable us to continue to do the highest quality clinical research and bring potentially life-changing care to patients who might benefit from this therapy." COMPASS's first US patent, No 10,519,175, was granted in December 2019 and covers the use of formulations of COMPASS's high-purity crystalline psilocybin in psilocybin therapy for patients with TRD. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Options CMPS Compass Pathways $38.27 / -1.24 (-3.14%) 02/09/21 Compass Pathways expands Discovery Center through lab collaborations 02/03/21 Compass announces publication on therapist training program for psilocybin 01/08/21 Compass Pathways establishes Center of Excellence with Sheppard Pratt 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 CMPS Compass Pathways $38.27 / -1.24 (-3.14%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg CMPS Compass Pathways $38.27 / -1.24 (-3.14%) 03/09/21 Compass Pathways reports Q4 EPS (52c), consensus ($1.05) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $38.27 / -1.24 (-3.14%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research CMPS Compass Pathways $38.27 / -1.24 (-3.14%) 10/21/20 Eleven new option listings and one option delisting on October 21st

Over a month ago
Earnings	Compass Pathways reports Q4 EPS (52c), consensus ($1.05) » 07:15 03/09/21 03/09 07:15 03/09/21 07:15 CMPS Compass Pathways $39.61 / -1.3 (-3.18%) George Goldsmith,… George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, "Mental health is an urgent crisis and this has only been exacerbated by the COVID-19 pandemic. At COMPASS we remain committed to transforming mental health care and helping patients who are suffering and aren't helped by existing treatments. Our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression is actively recruiting and we plan to report data from this trial at the end of the year. We are also continuing preclinical research into new indications, new compounds and new technologies, working with partners through our Centre of Excellence, our Discovery Center, and a number of investigator-initiated studies, as well as developing a strong team." ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Events Options CMPS Compass Pathways $39.61 / -1.3 (-3.18%) 02/09/21 Compass Pathways expands Discovery Center through lab collaborations 02/03/21 Compass announces publication on therapist training program for psilocybin 01/08/21 Compass Pathways establishes Center of Excellence with Sheppard Pratt 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 CMPS Compass Pathways $39.61 / -1.3 (-3.18%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg CMPS Compass Pathways $39.61 / -1.3 (-3.18%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $39.61 / -1.3 (-3.18%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research 03/09/21 Compass Pathways - CMPS CMPS Compass Pathways $39.61 / -1.3 (-3.18%) 10/21/20 Eleven new option listings and one option delisting on October 21st
Hot Stocks	Compass Pathways expands Discovery Center through lab collaborations » 07:27 02/09/21 02/09 07:27 02/09/21 07:27 CMPS Compass Pathways $45.70 / +0.69 (+1.53%) COMPASS Pathways… COMPASS Pathways announced that it has expanded its Discovery Center, through collaborations with world-leading laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin. Adam Halberstadt PhD, Associate Professor, Psychiatry, UC San Diego, and John D McCorvy PhD, Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, MCW, and their teams, will join Jason Wallach PhD, Assistant Professor of Pharmaceutical Sciences, University of the Sciences at the Discovery Center, a group of researchers working together, virtually. The COMPASS Discovery Center was established in August 2020 through a sponsored research agreement between COMPASS and University of the Sciences. It is led by Jason Wallach's laboratory at University of the Sciences and is now expanding its research network across the US, with Adam Halberstadt in San Diego, and John McCorvy in Wisconsin. The scientists intend to develop new, optimised psychedelic compounds to address unmet medical need. COMPASS will be the exclusive licensee for all new compounds generated. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Events Options CMPS Compass Pathways $45.70 / +0.69 (+1.53%) 02/03/21 Compass announces publication on therapist training program for psilocybin 01/08/21 Compass Pathways establishes Center of Excellence with Sheppard Pratt 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium CMPS Compass Pathways $45.70 / +0.69 (+1.53%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg CMPS Compass Pathways $45.70 / +0.69 (+1.53%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $45.70 / +0.69 (+1.53%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research 03/02/21 41st Annual Healthcare Virtual Conference CMPS Compass Pathways $45.70 / +0.69 (+1.53%) 10/21/20 Eleven new option listings and one option delisting on October 21st

Hot Stocks

Compass announces publication on therapist training program for psilocybin » 07:32

02/03/21

02/03

07:32

02/03/21

07:32

CMPS

Compass Pathways

$42.48 / +0.03 (+0.07%)

COMPASS Pathways has…

COMPASS Pathways has shared details of its comprehensive and rigorous therapist training programme for psilocybin therapy, in a paper jointly written with a group of academic researchers, and published in Frontiers in Psychiatry today. The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy. It is currently being used to train therapists taking part in COMPASS's phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration, as part of COMPASS's Investigational New Drug application. In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists. COMPASS developed the therapist training programme alongside leading experts in mental health and psychedelic research, including William A Richards, Elizabeth Nielson, Riikka Ajantaival, Peter Gasser, Sara J Tai, Brian D Richards, and Frederick Reinholdt. The programme uses a new and manualised approach drawing from evidence-based psychotherapeutic approaches, and currently comprises four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and professional development. In previous psilocybin studies, the approach to psychological support often varied between research sites, making it difficult to replicate and distinguish the specific effects of psilocybin from concurrent therapeutic interventions. Equally, training in the provision of psychological support had not been defined and evaluated. This manualised training programme begins to address this gap and is the start of a process that will continue to be refined and adapted as clinical trials of psilocybin therapy progress. Therapists who participated in the training reported that the combination of didactic and experiential learning helped them to build conceptual understanding and develop their skills in the therapeutic approach. From the programme feedback, the clinical training and engagement in participant care, under the guidance of experienced therapists, were considered to be the most beneficial and challenging aspects of the training.

ShowHide Related Items >><<

Company News
Street Research
Earnings
Syndicate
Periodicals
Events
Options

CMPS Compass Pathways

$42.48 / +0.03 (+0.07%)

CMPS Compass Pathways

$42.48 / +0.03 (+0.07%)

10/14/20 H.C. Wainwright: Compass Pathways initiated with a Buy at H.C. Wainwright

10/13/20 Evercore ISI: Compass Pathways initiated with an Outperform at Evercore ISI

10/13/20 Canaccord: Compass Pathways initiated with a Buy at Canaccord

10/13/20 Berenberg: Compass Pathways initiated with a Buy at Berenberg

CMPS Compass Pathways

$42.48 / +0.03 (+0.07%)

18

Sep

CMPS Compass Pathways

$42.48 / +0.03 (+0.07%)

CMPS Compass Pathways

$42.48 / +0.03 (+0.07%)

Over a quarter ago
Hot Stocks	Compass Pathways establishes Center of Excellence with Sheppard Pratt » 07:02 01/08/21 01/08 07:02 01/08/21 07:02 CMPS Compass Pathways $46.45 / -0.22 (-0.47%) COMPASS Pathway is… COMPASS Pathway is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States. The company said, "The Centre of Excellence will model the "clinic of the future", showcasing the best thinking in science, therapy, technology, and design. Working as a research facility and innovation lab, it will generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience. The first wave of research will focus on COMPASS's investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists...The Centre of Excellence will be led by Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, a distinguished fellow of the American Psychiatric Association and a fellow of the American College of Psychiatrists. The Centre of Excellence will be built on the Sheppard Pratt Towson campus and will include at least four state-of-the-art psychedelic therapy rooms, as well as facilities for research and training. In addition to a capital investment to support the design and building work, COMPASS will fund research studies into psilocybin therapy and other therapies, led by Dr Aaronson. " ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Events Options CMPS Compass Pathways $46.45 / -0.22 (-0.47%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares CMPS Compass Pathways $46.45 / -0.22 (-0.47%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg CMPS Compass Pathways $46.45 / -0.22 (-0.47%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) 18 Sep CMPS Compass Pathways $46.45 / -0.22 (-0.47%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research 01/11/21 2021 ICR Conference CMPS Compass Pathways $46.45 / -0.22 (-0.47%) 10/21/20 Eleven new option listings and one option delisting on October 21st
Conference/Events	Evercore ISI to hold a virtual conference » 04:55 12/03/20 12/03 04:55 12/03/20 04:55 CMPS Compass Pathways $47.94 / +3.21 (+7.18%) , INSM Insmed $39.74 / +0.71 (+1.82%) , ALXN Alexion $122.70 / +0.55 (+0.45%) , ENTA Enanta $42.11 / +1.06 (+2.58%) , NKTX Nkarta $33.99 / -0.02 (-0.06%) , HRC Hill-Rom $96.12 / -0.16 (-0.17%) , DRNA Dicerna $24.45 / -0.31 (-1.25%) , ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) , INCY Incyte $82.30 / -3.14 (-3.68%) , MTEM Molecular Templates $8.68 / -0.16 (-1.81%) , KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) , ICLR Icon $199.11 / +1.67 (+0.85%) , MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) , NVST Envista $31.12 / +1.06 (+3.53%) , EXEL Exelixis $19.32 / +0.17 (+0.89%) , FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) , FOLD Amicus $23.25 / +0.58 (+2.56%) , COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) , BHC Bausch Health $19.06 / +0.42 (+2.25%) , TBIO Translate Bio $22.49 / +0.25 (+1.12%) , STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) , PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.49 / +0.25 (+1.12%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $31.12 / +1.06 (+3.53%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $33.99 / -0.02 (-0.06%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.74 / +0.71 (+1.82%) 12/02/20 Insmed initiates Phase 3 study of Brensocatib in patients with bronchiectasis 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM INCY Incyte $82.30 / -3.14 (-3.68%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $199.11 / +1.67 (+0.85%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $96.12 / -0.16 (-0.17%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $23.25 / +0.58 (+2.56%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.32 / +0.17 (+0.89%) 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo ENTA Enanta $42.11 / +1.06 (+2.58%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $24.45 / -0.31 (-1.25%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $122.70 / +0.55 (+0.45%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.74 / +0.71 (+1.82%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $122.70 / +0.55 (+0.45%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $42.11 / +1.06 (+2.58%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $33.99 / -0.02 (-0.06%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $96.12 / -0.16 (-0.17%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $24.45 / -0.31 (-1.25%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $82.30 / -3.14 (-3.68%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $199.11 / +1.67 (+0.85%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $31.12 / +1.06 (+3.53%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.32 / +0.17 (+0.89%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 12/02/20 Barclays Fate Therapeutics price target raised to $70 from $60 at Barclays 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer FOLD Amicus $23.25 / +0.58 (+2.56%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.49 / +0.25 (+1.12%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 12/02/20 Stifel Sutro Biopharma initiated with a Buy at Stifel 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $31.12 / +1.06 (+3.53%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.74 / +0.71 (+1.82%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $82.30 / -3.14 (-3.68%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $199.11 / +1.67 (+0.85%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $96.12 / -0.16 (-0.17%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $23.25 / +0.58 (+2.56%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.32 / +0.17 (+0.89%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $42.11 / +1.06 (+2.58%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $24.45 / -0.31 (-1.25%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $122.70 / +0.55 (+0.45%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.49 / +0.25 (+1.12%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $23.25 / +0.58 (+2.56%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $122.70 / +0.55 (+0.45%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.49 / +0.25 (+1.12%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $31.12 / +1.06 (+3.53%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $33.99 / -0.02 (-0.06%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $23.25 / +0.58 (+2.56%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $42.11 / +1.06 (+2.58%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $122.70 / +0.55 (+0.45%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta 12/15/20 Hill-Rom ALXN ALXN Alexion $122.70 / +0.55 (+0.45%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $82.30 / -3.14 (-3.68%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $122.70 / +0.55 (+0.45%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names
Conference/Events	Evercore ISI to hold a virtual conference » 04:55 12/02/20 12/02 04:55 12/02/20 04:55 CMPS Compass Pathways $44.73 / -4.78 (-9.65%) , INSM Insmed $39.05 / +0.03 (+0.08%) , ALXN Alexion $122.16 / +0.19 (+0.16%) , ENTA Enanta $41.12 / +0.01 (+0.02%) , NKTX Nkarta $34.02 / +1.09 (+3.31%) , HRC Hill-Rom $96.26 / +1.325 (+1.40%) , DRNA Dicerna $24.76 / -0.53 (-2.10%) , ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) , INCY Incyte $85.42 / +0.9 (+1.06%) , MTEM Molecular Templates $8.85 / -0.1 (-1.12%) , KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) , ICLR Icon $197.44 / +2.59 (+1.33%) , MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) , NVST Envista $30.06 / +0.31 (+1.04%) , EXEL Exelixis $19.15 / +0.02 (+0.10%) , FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) , FOLD Amicus $22.66 / -0.28 (-1.22%) , COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) , BHC Bausch Health $18.65 / +0.065 (+0.35%) , TBIO Translate Bio $22.25 / +0.03 (+0.14%) , STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) , PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.25 / +0.03 (+0.14%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $30.06 / +0.31 (+1.04%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $34.02 / +1.09 (+3.31%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.05 / +0.03 (+0.08%) 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM 07/24/20 Insmed's Arikayce for lung infections receives positive CHMP opinion in EU INCY Incyte $85.42 / +0.9 (+1.06%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $197.44 / +2.59 (+1.33%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $96.26 / +1.325 (+1.40%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $22.66 / -0.28 (-1.22%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.15 / +0.02 (+0.10%) 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo ENTA Enanta $41.12 / +0.01 (+0.02%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $24.76 / -0.53 (-2.10%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $122.16 / +0.19 (+0.16%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.05 / +0.03 (+0.08%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $122.16 / +0.19 (+0.16%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $41.12 / +0.01 (+0.02%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $34.02 / +1.09 (+3.31%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $96.26 / +1.325 (+1.40%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $24.76 / -0.53 (-2.10%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $85.42 / +0.9 (+1.06%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $197.44 / +2.59 (+1.33%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $30.06 / +0.31 (+1.04%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.15 / +0.02 (+0.10%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer 11/06/20 Piper Sandler Fate Therapeutics price target raised to $71 from $59 at Piper Sandler FOLD Amicus $22.66 / -0.28 (-1.22%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.25 / +0.03 (+0.14%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies 07/16/20 Wells Fargo Sutro Biopharma initiated with an Overweight at Wells Fargo PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $30.06 / +0.31 (+1.04%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.05 / +0.03 (+0.08%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $85.42 / +0.9 (+1.06%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $197.44 / +2.59 (+1.33%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $96.26 / +1.325 (+1.40%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $22.66 / -0.28 (-1.22%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.15 / +0.02 (+0.10%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $41.12 / +0.01 (+0.02%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $24.76 / -0.53 (-2.10%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $122.16 / +0.19 (+0.16%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.25 / +0.03 (+0.14%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $22.66 / -0.28 (-1.22%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $122.16 / +0.19 (+0.16%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.25 / +0.03 (+0.14%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $30.06 / +0.31 (+1.04%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $34.02 / +1.09 (+3.31%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $22.66 / -0.28 (-1.22%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $41.12 / +0.01 (+0.02%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $122.16 / +0.19 (+0.16%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/02/20 32nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta 12/15/20 Hill-Rom ALXN ALXN Alexion $122.16 / +0.19 (+0.16%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $85.42 / +0.9 (+1.06%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $122.16 / +0.19 (+0.16%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names
Conference/Events	Evercore ISI to hold a virtual conference » 08:22 12/01/20 12/01 08:22 12/01/20 08:22 CMPS Compass Pathways $49.60 / +2.26 (+4.77%) , INSM Insmed $39.02 / -0.8 (-2.01%) , ALXN Alexion $121.96 / -2.03 (-1.64%) , ENTA Enanta $41.32 / -1.5 (-3.50%) , NKTX Nkarta $32.91 / -1.23 (-3.60%) , HRC Hill-Rom $94.86 / -0.71 (-0.74%) , DRNA Dicerna $25.32 / +0.79 (+3.22%) , ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) , INCY Incyte $84.52 / +1.33 (+1.60%) , MTEM Molecular Templates $8.93 / -0.18 (-1.98%) , KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) , ICLR Icon $194.85 / +4.45 (+2.34%) , MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) , NVST Envista $29.75 / +0.14 (+0.47%) , EXEL Exelixis $19.16 / -0.26 (-1.34%) , FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) , FOLD Amicus $22.94 / -0.31 (-1.33%) , COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) , BHC Bausch Health $18.58 / -0.97 (-4.96%) , TBIO Translate Bio $22.24 / +2.9 (+14.99%) , STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) , PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.24 / +2.9 (+14.99%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $29.75 / +0.14 (+0.47%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $32.91 / -1.23 (-3.60%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.02 / -0.8 (-2.01%) 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM 07/24/20 Insmed's Arikayce for lung infections receives positive CHMP opinion in EU INCY Incyte $84.52 / +1.33 (+1.60%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $194.85 / +4.45 (+2.34%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $94.86 / -0.71 (-0.74%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $22.94 / -0.31 (-1.33%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.16 / -0.26 (-1.34%) 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo ENTA Enanta $41.32 / -1.5 (-3.50%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $25.32 / +0.79 (+3.22%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $121.96 / -2.03 (-1.64%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.02 / -0.8 (-2.01%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $121.96 / -2.03 (-1.64%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $41.32 / -1.5 (-3.50%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $32.91 / -1.23 (-3.60%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $94.86 / -0.71 (-0.74%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $25.32 / +0.79 (+3.22%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $84.52 / +1.33 (+1.60%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $194.85 / +4.45 (+2.34%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $29.75 / +0.14 (+0.47%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.16 / -0.26 (-1.34%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer 11/06/20 Piper Sandler Fate Therapeutics price target raised to $71 from $59 at Piper Sandler FOLD Amicus $22.94 / -0.31 (-1.33%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.24 / +2.9 (+14.99%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies 07/16/20 Wells Fargo Sutro Biopharma initiated with an Overweight at Wells Fargo PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $29.75 / +0.14 (+0.47%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.02 / -0.8 (-2.01%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $84.52 / +1.33 (+1.60%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $194.85 / +4.45 (+2.34%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $94.86 / -0.71 (-0.74%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $22.94 / -0.31 (-1.33%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.16 / -0.26 (-1.34%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $41.32 / -1.5 (-3.50%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $25.32 / +0.79 (+3.22%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $121.96 / -2.03 (-1.64%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.24 / +2.9 (+14.99%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $22.94 / -0.31 (-1.33%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $121.96 / -2.03 (-1.64%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.24 / +2.9 (+14.99%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $29.75 / +0.14 (+0.47%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $32.91 / -1.23 (-3.60%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $22.94 / -0.31 (-1.33%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $41.32 / -1.5 (-3.50%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $121.96 / -2.03 (-1.64%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/02/20 32nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta ALXN ALXN Alexion $121.96 / -2.03 (-1.64%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $84.52 / +1.33 (+1.60%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $121.96 / -2.03 (-1.64%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names

06:11	GameStop downgraded to Sell from Hold at Ascendiant»
05:33	Canaccord upgrades Tesla with over $1,000 target on 'Apple-esque' ecosystem»
20:05	Fly Intel: Top five weekend stock stories»
16:09	On The Fly: Weekly technical notes for Russell 2000»
15:54	On The Fly: Weekly technical notes for S&P 500»

ATXI	PDUFA Date for
GNRS	Greenrose Acquisition - GNRS
	Spring 2021 Transmission, Distribution, Meeting & Mutual Assistance Virtual Conference
ONCY	KOL Webinar on AWARE-1 Data
GRCL ...	20th Annual Virtual Healthcare Virtual Conference
	AACR Virtual Annual Meeting 2021
BWEN	Broadwind
TCRR	TCR2 Therapeutics
	Leisure Products
ITOS	iTeos Therapeutics - ITOS

Get Full Fly Access